Recently adopted names for antitumoral compounds (April 2012) - Noms d’antitumoraux adoptés récemment (avril 2012) - Birinapant, demcizumab, etirinotecan pegol, pexastimogene devacirepvec, rabusertib, rimilogene galvacirepvec, vintafolide

Birinapant, demcizumab, etirinotecan pegol, pexastimogene devacirepvec, rabusertib, rimilogene galvacirepvec, vintafolide

Name (nom)	Code name	Type	Target(s)
birinapant	TL32711	Synthetic small peptidomimetic molecule	Smac ( Second mitochondrial-derived activator of caspases)
demcizumab	OMP-21M18	Monoclonal antibody	Delta-like 4 ligand (DLL4), an activator of Notch signaling
etirinotecan pegol	NKTR-102	Irinotecan conjugate	Topoisomerase I
pexastimogene devacirepvec	JX-594, TG6006	Thymidine kinase-deleted oncolytic poxvirus	Cancer cells
rabusertib	LY2603618, IC-83	Small inhibitory molecule	Cell cycle checkpoint kinase  (chk)
rimilogene galvacirepvec	Prostvac-V	Recombinant vaccinia virus vaccine	Prostate-specific antigen (PSA)
vintafolide	EC145	Vinca alkaloid conjugate	Microtubules